Embedded Files
The Future in the Fight Against COVID-19 is HERE
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld™ (tixagevimab and cilgavimab). Evusheld is a potent new COVID-19 protective measure (monoclonal antibody) designed to prevent COVID-19 infection in vulnerable and immunocompromised individuals who may not mount an adequate immune response to COVID-19 vaccination.
Think you are eligable to receive Evusheld? Talk to your provider today and ask for a prescription.
Are you a Healthcare Provider?
Access the Prescription Order Form and Resource Page for more information
FAX: (405) 454-7611 Phone: (405) 805-6191
What is Evusheld?
What is Evusheld?
In immunocompromised patients, a vaccination may not generate enough immune response, so they are still vulnerable to severe infection. Evusheld gives additional immunity to help prevent COVID-19.
Evusheld is a combination of two monoclonal antibodies, given in two consecutive injections in one visit to qualifying patients who do not have COVID-19.
How is it Administered?
How is it Administered?
Evusheld is administered by giving two shots by intramuscular (IM) injection in the gluteal region injecting one shot right after the other.
A one hour monitoring period will follow after administration so you can expect the entire process to take 75-90 minutes.
Who is Eligable?
Who is Eligable?
Adults and pediatric individuals (12 years of age and older weighing at least 88 pounds 40 kg):
Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2, AND:
Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination, OR
For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).
Learn More About EVUSHELD
EVUSHELDTM long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies
Learn About Evusheld and Protecting Patients with Compromised Immune Systems
Learn About Evusheld and Protecting Patients with Compromised Immune Systems
How Does a Mobile Monoclonal Antibody Appointment Work?
If you do qualify, consent and have a valid prescription; an appointment will be booked and payment will be made at that time. Our goal is to administer Evusheld same day when we have the therapy available including weekends.
This is a Mobile appointment, we will bring the medication to you and administer in the convenience of your home.
Please note that this is ONLY for pre-exposure prophylaxis (you have not been exposed) to COVID-19. Please note that a negative COVID-19 Test is required to receive this medication per our policy. A Rapid Antigen Test will be preformed as part of our service.
If you do not currently have a prescription, we can work with your doctor's office; please give us a call.
We are not credentialed with insurance companies, so you may choose to private pay the $300 charge and ask for reimbursement from your insurance. You will be provided a Superbill to ask for reimbursement from your insurance.
Page updated
Report abuse